240 related articles for article (PubMed ID: 12417045)
1. Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil).
Tsukioka Y; Matsumura Y; Hamaguchi T; Koike H; Moriyasu F; Kakizoe T
Jpn J Cancer Res; 2002 Oct; 93(10):1145-53. PubMed ID: 12417045
[TBL] [Abstract][Full Text] [Related]
2. Development of the polymer micelle carrier system for doxorubicin.
Nakanishi T; Fukushima S; Okamoto K; Suzuki M; Matsumura Y; Yokoyama M; Okano T; Sakurai Y; Kataoka K
J Control Release; 2001 Jul; 74(1-3):295-302. PubMed ID: 11489509
[TBL] [Abstract][Full Text] [Related]
3. Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity.
Nishida K; Kashiwagi M; Shiba S; Muroki K; Ohishi A; Doi Y; Ando H; Ishida T; Nagasawa K
Toxicol Appl Pharmacol; 2017 Dec; 337():76-84. PubMed ID: 29054682
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin.
Matsumura Y; Hamaguchi T; Ura T; Muro K; Yamada Y; Shimada Y; Shirao K; Okusaka T; Ueno H; Ikeda M; Watanabe N
Br J Cancer; 2004 Nov; 91(10):1775-81. PubMed ID: 15477860
[TBL] [Abstract][Full Text] [Related]
5. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
Arabi L; Badiee A; Mosaffa F; Jaafari MR
J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
[TBL] [Abstract][Full Text] [Related]
6. Electrosprayed Myocet-like Liposomes: An Alternative to Traditional Liposome Production.
Collier MA; Bachelder EM; Ainslie KM
Pharm Res; 2017 Feb; 34(2):419-426. PubMed ID: 27896588
[TBL] [Abstract][Full Text] [Related]
7. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
Charrois GJ; Allen TM
Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
[TBL] [Abstract][Full Text] [Related]
8. Radiolabeled liposome imaging determines an indication for liposomal anticancer agent in ovarian cancer mouse xenograft models.
Ito K; Hamamichi S; Asano M; Hori Y; Matsui J; Iwata M; Funahashi Y; Umeda IO; Fujii H
Cancer Sci; 2016 Jan; 107(1):60-7. PubMed ID: 26509883
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination.
Fonseca NA; Gomes-da-Silva LC; Moura V; Simões S; Moreira JN
J Control Release; 2014 Dec; 196():122-31. PubMed ID: 25305563
[TBL] [Abstract][Full Text] [Related]
10. Development of pH-sensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood.
Ishida T; Okada Y; Kobayashi T; Kiwada H
Int J Pharm; 2006 Feb; 309(1-2):94-100. PubMed ID: 16364578
[TBL] [Abstract][Full Text] [Related]
11. Rapid Analysis of DOXIL Stability and Drug Release from DOXIL by HPLC Using a Glycidyl Methacrylate-Coated Monolithic Column.
Kimoto A; Watanabe A; Yamamoto E; Higashi T; Kato M
Chem Pharm Bull (Tokyo); 2017; 65(10):945-949. PubMed ID: 28966279
[TBL] [Abstract][Full Text] [Related]
12. Albumin-conjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in rats.
Yokoe J; Sakuragi S; Yamamoto K; Teragaki T; Ogawara K; Higaki K; Katayama N; Kai T; Sato M; Kimura T
Int J Pharm; 2008 Apr; 353(1-2):28-34. PubMed ID: 18082345
[TBL] [Abstract][Full Text] [Related]
13. Application of nanoparticle technology for the prevention of restenosis after balloon injury in rats.
Uwatoku T; Shimokawa H; Abe K; Matsumoto Y; Hattori T; Oi K; Matsuda T; Kataoka K; Takeshita A
Circ Res; 2003 Apr; 92(7):e62-9. PubMed ID: 12663484
[TBL] [Abstract][Full Text] [Related]
14. Specific Targeting of PEGylated Liposomal Doxorubicin (Doxil
Aldughaim MS; Muthana M; Alsaffar F; Barker MD
Molecules; 2020 Dec; 26(1):. PubMed ID: 33379361
[TBL] [Abstract][Full Text] [Related]
15. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models.
Peer D; Margalit R
Neoplasia; 2004; 6(4):343-53. PubMed ID: 15256056
[TBL] [Abstract][Full Text] [Related]
16. Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations.
Luo R; Li Y; He M; Zhang H; Yuan H; Johnson M; Palmisano M; Zhou S; Sun D
Int J Pharm; 2017 Mar; 519(1-2):1-10. PubMed ID: 28063903
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors.
Kibria G; Hatakeyama H; Sato Y; Harashima H
Int J Pharm; 2016 Jul; 509(1-2):178-187. PubMed ID: 27234700
[TBL] [Abstract][Full Text] [Related]
18. S-Nitrosated human serum albumin dimer as novel nano-EPR enhancer applied to macromolecular anti-tumor drugs such as micelles and liposomes.
Kinoshita R; Ishima Y; Ikeda M; Kragh-Hansen U; Fang J; Nakamura H; Chuang VT; Tanaka R; Maeda H; Kodama A; Watanabe H; Maeda H; Otagiri M; Maruyama T
J Control Release; 2015 Nov; 217():1-9. PubMed ID: 26302904
[TBL] [Abstract][Full Text] [Related]
19. Leakage kinetics of the liposomal chemotherapeutic agent Doxil: The role of dissolution, protonation, and passive transport, and implications for mechanism of action.
Russell LM; Hultz M; Searson PC
J Control Release; 2018 Jan; 269():171-176. PubMed ID: 29122661
[TBL] [Abstract][Full Text] [Related]
20. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
